Abstract: mutations are respectively rare in gastrointestinal stromal tumors (GIST). Most GIST with PDGFRA exon 18 mutations including D842V mutation are highly resistant to imatinib. The treatment of GIST harboring primary drug-resistant mutation is a major challenge. This article aims to investigate clinicopathologic features of GIST with -D842V mutation and the efficacy of comprehensive treatment, providing a reference for clinical practice. A retrospective cohort study was conducted to collect the clinicopathological and follow-up data of patients with GIST harboring mutation who were diagnosed and treated in the GIST Clinic of Renji Hospital from January 2005 to May 2020. According to the mutation site, the enrolled patients were divided into D842V mutation group and non-D842V mutation group. The differences of clinicopathologic characteristics between the two groups were compared. Furthermore, overall survival and prognostic factors were analyzed. A total of 71 patients with -mutant GIST were included in this study, including 47 cases of D842V mutation (66.2%) and 24 cases of non-D842V mutation (33.8%). There were 28 male patients and 19 female patients in D842V mutation group, with a median age of 60 (36-82) years. There were 16 male patients and 8 female patients in non-D842V mutation group, with a median age of 62 (30-81) years. There were no significant differences in age, gender, primary location, surgical procedure, tumor size, mitotic count, expression of CD117 and DOG1, Ki-67 proliferation index and modified NIH grade between the two groups (all >0.05). The positive rate of CD34 was 89.4% (42/47) and 62.5% (15/24) in the D842V mutation group and the non-D842V mutation group, respectively, with a statistically significant difference (χ(2)=5.644, =0.018). Among all the cases, 66 cases underwent R0 resection without preoperative treatment; two cases underwent emergency operation with R1 resection because of tumor rupture; 2 cases were not operated after the pathological and mutation types were confirmed by biopsy (one case received avapritinib treatment and obtain partial remission). One case was diagnosed as wild-type GIST per needle biopsy in another institute, and underwent R0 resection after preoperative imatinib treatment for 6 months. After surgery, 5 high-risk GIST patients with D842V mutation and 5 high-risk GIST patients with non-D842V mutation were treated with imatinib for more than one year. The median follow-up time was 37 (1-153) months. As of the last follow-up among the patients who received R0 resection, 4 patients with D842V mutation had relapse, of whom 1 was in the period of imatinib administration, and the 3-year relapse-free survival rate was 94.2%; none of the patients with non-D842V mutation had relapse. There was no statistically significant difference in relapse-free surivval between two groups (=0.233). Univariate analysis revealed that mitotic count (=0.002), Ki-67 proliferation index (<0.001) and modified NIH grade (=0.025) were the factors associated with relapse-free survival of patients with D842V mutation after R0 resection (all <0.05). However, the above factros were not testified as independant prognostic facors in multivariate Cox analysis (all <0.05). Clinicopathologic features and the efficacy of radical resection in patients with PDGFRA-D842V mutation are similar to those in patients with non-D842V mutation.

Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China

Clinicopathologic Characteristics and Prognosis of &Lt;i>pdgfra</i>-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China

Surgical Management and Outcomes of Duodenal Gastrointestinal Stromal Tumors.

Gastrointestinal Stromal Tumors of the Duodenum: Surgical Management and Survival Results

[Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].

Clinicopathological Features and Prognosis of 59 Patients with Platelet-Derived Growth Factor Α-Mutant Gastrointestinal Stromal Tumor

Clinical characteristics and prognosis of primary gastrointestinal stromal tumors with PDGFRα mutation

Prognostic Factors for Primary Localized Gastrointestinal Stromal Tumors after Radical Resection: Shandong Gastrointestinal Surgery Study Group, Study 1201

[Analysis of Biological Characteristics and Prognosis on Gastrointestinal Stromal Tumor with PDGFRA Gene Mutation].

Prognostic Model for Recurrence-Free Survival after Surgical Resection of Primary Gastric Gastrointestinal Stromal Tumors

Comprehensive analysis of factors that involve in survival and prognosis in patients with gastrointestinal stromal tumors

Resection of GIST in the Duodenum and Proximal Jejunum: A Retrospective Analysis of Outcomes

[Clinicopathological Features and Prognostic Factors of Gastric Intermediate-Risk Gastrointestinal Stromal Tumor after Surgical Resection: a Retrospective Study].

Mutational Characteristics of Gastrointestinal Stromal Tumors: A Single-Center Analysis of 302 Patients

Clinicopathological and Therapeutic Analysis of PDGFRA Mutated Gastrointestinal Stromal Tumor.

Clinicopathological and Prognostic Features of Surgical Management in Duodenal Gastrointestinal Stromal Tumors

Impact of Kit and Pdgfra Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors after Complete Primary Tumor Resection

[Analysis of Clinicopathology and Prognosis in 181 Patients with Gastrointestinal Stromal Tumors].

Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers.

Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors

[Prognostic Analysis of 349 Cases with Gastrointestinal Stromal Tumor].